Transgene SA
11 rue de MOLSHEIM, 67082
Strasbourg
Cedex
France
Tel: 011-33-3-88-27-91-21
Fax: 011-33-3-88-27-91-11
Website: http://www.transgene.fr/
327 articles about Transgene SA
-
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
3/5/2024
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation, a leader in IT, network and AI technologies and BostonGene Corporation, a leading company in AI-based molecular and immune profiling, announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.
-
Transgene Announces Upcoming January 2024 Investor Meetings
12/21/2023
TRANSGENE announces that Management will participate in several investor events in the upcoming investor events, as set out below.
-
5 Cancer Vaccines to Watch in 2024
11/20/2023
BioSpace takes a deep dive into five investigational therapeutic cancer vaccines that have recently shown efficacy in difficult-to-treat indications. -
Transgene Reports Business Update and Q3 2023 Financial Position
11/7/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its business update and its financial position for the quarter ending September 30, 2023.
-
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
10/10/2023
Transgene and BioInvent International AB announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.
-
BioInvent and Transgene: First patient treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)
10/10/2023
BioInvent International AB and Transgene announce that that the first patient of the Phase 1 part B clinical trial evaluating the combination of BT-001 and MSD's anti-PD-1 therapy, KEYTRUDA® has been dosed.
-
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024
9/20/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results for the six-month period ended June 30, 2023, and provides an update on its product pipeline and upcoming plans.
-
Transgene Announces Upcoming Investor Meetings - September 14, 2023
9/14/2023
TRANSGENE, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that Management will participate in several investor events, as set out below.
-
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
7/17/2023
Regulatory News: Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million as a result of the full disposal of its minority stake in a Chinese biopharmaceutical company.
-
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
6/6/2023
Transgene and NEC Corporation announced that new data have been presented on TG4050, an individualized neoantigen cancer vaccine, at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities.
-
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
6/5/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented on TG4001.
-
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology annual meeting to be held in Chicago, IL.
-
BioInvent and Transgene Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors
5/25/2023
BioInvent International AB and Transgene announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors.
-
Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
5/25/2023
Transgene and BioInvent International AB announce positive Phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors.
-
Transgene provides business update and Q1 2023 financial position
5/10/2023
Regulatory News: Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, provides a business update, including its financial position as of March 31, 2023.
-
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
5/10/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical trial evaluating TG6050.
-
Transgene’s Combined General Meeting of May 5, 2023
5/5/2023
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 9:00 a.m. at the Company’s headquarters.
-
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
5/5/2023
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board has appointed Dr Alessandro Riva, MD, as the Company’s new Chairman and CEO to accelerate the development of its innovative immunotherapy portfolio.
-
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
-
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
4/18/2023
Transgene and NEC Corporation announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research Annual Meeting in Orlando, Florida.